Clinical Trial Search

Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume

Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg

Primary: Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Prinicple Investigator — 19 participants

Primary: Change in Limb Fat (g) From Baseline — 74; 110 grams — p=0.64

Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94

Primary: Change in Fat mtDNA Content — -169; 321 copies/cell

Primary: Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48 — 0.02; -0.02; 0.02; -0.01 ratio — p=0.48

Primary: Change From 6 Months to Baseline in Visual Analogue Scale (VAS) Pain After 15 Minutes of Sitting — -28.1 mm

Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2

Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049

Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell

Primary: Total Limb Fat Mass — 8.84; 9.13 kg

Primary: Fasting Serum Triglycerides — 237; 341 mg/dL — p=0.84

Primary: Change From Baseline in Limb Fat at Week 48 — 392; -257 grams (g) — p=0.0014

Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02

Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min

Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale

Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001

Primary: Serum Lipid Levels — 228.8; 219.7; 113.0; 105.7 mg/dl

Primary: Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2) — -6.6; 1.8 cm^2 — p=0.52

Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h

Primary: Changes From Baseline in Fasting Blood Glucose at Week 52 — 0; -2; 1 mg/dL — p=>0.05

Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001

Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL

Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04

Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…

Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013

Primary: Change in Mitochondrial Activity — 1250; 1312; 1150; 1125 copies/cell

Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1

Primary: Hepatic Steatosis